Study of the Efficacy of Chloroquine in the Treatment of Ductal Carcinoma in Situ (The PINC Trial)

Phase 1/2 Completed 12 enrolled Inova Health Care Services George Mason University · collab U.S. Army Medical Research and Development Command · collab United States Department of Defense · collab University of Pittsburgh Medical Center · collab

Non-randomizedParallel-groupOpen-labelTreatment

Summary

The purpose of this study is to test the hypothesis that chloroquine will reduce the ability of ductal carcinoma in situ (DCIS) to survive and spread. Participants will receive either chloroquine standard dose (500mg/week) or chloroquine low dose (250mg/week) for 1 month prior to surgical removal of the tumor.

Timeline

Start: 2009-12
Primary completion: 2016-10
Completion: 2016-10

Publications

Martinez-Outschoorn UE, Pavlides S, Whitaker-Menezes D, Daumer KM, Milliman JN, Chiavarina B, Migneco G, Witkiewicz AK, Martinez-Cantarin MP, Flomenberg N, Howell A, Pestell RG, Lisanti MP, Sotgia F. Tumor cells induce the cancer associated fibroblast phenotype via caveolin-1 degradation: implications for breast cancer and DCIS therapy with autophagy inhibitors. Cell Cycle. 2010 Jun 15;9(12):2423-33. doi: 10.4161/cc.9.12.12048. Epub 2010 Jun 15.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Chloroquine	Small molecule	250 mg	—
Subject	Chloroquine	Small molecule	500 mg	—

Study of the Efficacy of Chloroquine in the Treatment of Ductal Carcinoma in Situ (The PINC Trial)

Summary

Timeline

Publications

Drugs

Indications